Optimizing HIV prevention for highly vulnerable methamphetamine-using sexual minority men

Active Cooperative Agreement Awarded Last action

Award ID
UH3AI169652
Recipient
Awarding agency
Obligated
$6,343,591

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 90% complete
Place of performance
New York, NY 10027, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
This lite-2 (RFA-AI-21-018) initiative responds to a resurgent epidemic of methamphetamine (METH) use in sexual minority men (SMM), which is a primary driver of HIV incidence. The overarching goals are two-fold: 1) identify multi-level and BIO-behavioral determinants of amplified HIV seroconversion risk in METH-using SMM; and 2) test the effectiveness of telehealth motivational enhancement interventions for optimizing entry or RE-entry of SMM who use METH into the prep care continuum. Findings from our lite-1 cohort (UG3/UH3 AI-133675, RFA-AI-16-031) and others provide compelling evidence that METH use is increasing, disproportionally impacts racial/ethnic minorities, and accounts for one-in-three new HIV infections in SMM. In response to lite-2 (RFA- AI-21-018) we propose a multi-component initiative zeroing in on the "where," "how," and "why" of METH use and HIV risk. Where: what are the geospatial determinants of the association of METH use with HIV incidence? How: how can we support (RE-)entry into the prep care continuum with this high priority population of SMM who use METH? Why: does METH amplify biological risk of HIV by potentiating rectal immune dysregulation? Aim 1: examine multi-level structural, psychological, and social determinants of amplified HIV seroconversion risk in SMM who use METH. The centerpiece of our lite-2 initiative is a new prospective, BIO-behavioral cohort with N=5,000 SMM (N=3,000 SMM who use METH, N=2,000 who do not). Participants will complete assessments over 36 months and provide biological samples for HIV testing, drug toxicology testing, rectal stis, and rectal cytokines/chemokines. Our primary goal will be to investigate the role of geospatial determinants (e.g., background METH and HIV prevalence, urbanicity) and other structural determinants (e.g., structural stigma of sexual minorities as evidenced by policies/laws) in relation to the association of METH use with amplified HIV seroconversion risk. Aim 2: test the comparative and combined effectiveness of telehealth motivational enhancement interventions for optimizing prep use. Prep readiness interventions for supporting motivation (PRISM) is a hybrid type I, modified factorial randomized controlled trial (RCT) of telehealth CM that provides incentives for filling a prep prescription, and a 2-session telehealth MI intervention that we adapted with METH- using SMM (R34-DA046367, carrico/grov). PRISM will enroll 840 METH-using SMM who are not currently taking prep from the lite-2 cohort (aim 1) to examine the effectiveness of CM (N = 280), MI (N = 280), and MI+CM (N = 280) on the primary outcome - filling a prep prescription. Aim 3: determine whether greater rectal immune dysregulation partially explains amplified risk of HIV seroconversion in SMM who use METH. Using a case-cohort design, we will compare HIV seroconverters (N=450) with matched seronegative controls (N=450) to examine the clinical relevance of METH-induced alterations in rectal cytokines with respect to HIV seroconversion. This lite-2 initiative could have an exceptional impact by transforming HIV prevention with SMM.

Transactions

Action Obligated Date
Amendment $1,049,856
Amendment $0
Amendment $0
Amendment $1,896,599
Amendment $500,000
Amendment Optimizing HIV prevention for high-risk methamphetamine-using men who have SEX with men - modified project summary/abstract section this lite-2… $500,000
Amendment $169,169
Amendment Optimizing HIV prevention for high-risk methamphetamine-using men who have SEX with men - modified project summary/abstract section this lite-2… $169,169
Amendment $1,558,797
Original award $500,000

Subawards

Subrecipient Amount Awarded
Florida International University KEY PERSONNEL Adam W. Carrico, Ph.D., Multiple Principal Investigator (0.05 calendar months) is a Professor and Chair in the Robert Stempel College of Public… $133,071
The Administrators Of Tulane Educational Fund Key Personnel: Jennifer Manuzak, PhD, Primary Investigator (1.2 months, 10%) Dr. Manuzak is an Assistant Professor in the Division of Immunology at the Tulane… $274,910
University Of Miami KEY PERSONNEL Kathryn McCollister, Ph.D., Site Principal Investigator/Co-Investigator (Year 4: 0.84 calendar months) is a Professor and Health Economist in… $40,300
Albert Einstein College Of Medicine A. SENIOR/KEY PERSONNEL Viraj Patel, MD, MPH (Co-Investigator) is a physician-scientist and Associate Professor, Division of General Internal Medicine. He is… $34,539
Florida International University KEY PERSONNEL Adam W. Carrico, Ph.D., Multiple Principal Investigator (0.05 calendar months) is a Professor and Chair in the Robert Stempel College of Public… $56,936
University Of Florida Budget Justification The University of Florida (UF) employs Dr. Westmoreland and, as such, all of her related study activities will occur at UF. UF will not… $15,000
Florida International University KEY PERSONNEL Adam W. Carrico, Ph.D., Multiple Principal Investigator (0.05 calendar months) is a Professor and Chair in the Robert Stempel College of Public… $130,000

Quick answers

Who received award UH3AI169652?

UH3AI169652 was awarded to Research Foundation Of The City University Of New York by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 8, 2022.

How much is award UH3AI169652 worth?

$6,343,591 has been obligated on UH3AI169652.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login